DVT complete diagnostic approach resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
Line 143: | Line 143: | ||
== Anticoagulation== | == Anticoagulation== | ||
===Warfarin== | ===Warfarin=== | ||
* Begin with 10 mg warfarin for 2 days followed by dosing based on the INR | * Begin with 10 mg warfarin for 2 days followed by dosing based on the INR | ||
* Start at the 1st or 2nd day of the initial parenteral therapy | * Start at the 1st or 2nd day of the initial parenteral therapy | ||
Line 150: | Line 150: | ||
** If stable, repeat INR every 12 weeks | ** If stable, repeat INR every 12 weeks | ||
** If stable but one value 0.5 below or above the target range, continue the same dose and repeat INR within 1-2 weeks | ** If stable but one value 0.5 below or above the target range, continue the same dose and repeat INR within 1-2 weeks | ||
* Avoid NSAIDs, COX2 selective NSAIDs and some antibiotics | * Avoid NSAIDs, COX2 selective NSAIDs and some antibiotics<ref name="pmid22315259">{{cite journal| author=Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al.| title=Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e152S-84S | pmid=22315259 | doi=10.1378/chest.11-2295 | pmc=PMC3278055 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315259 }} </ref> | ||
==Heparin== | ==Heparin== |
Revision as of 14:36, 22 May 2014
Complete Diagnostic Approach
A complete diagnostic approach should be carried out after a focused initial rapid evaluation is conducted and following initiation of any urgent intervention.[1]
Identify possible precipitating factors: Obtain a detailed history:
❑ Past medical history:
❑ Abortion at second or third trimester of pregnancy (suggestive of an inherited thrombophilia or APS) | |||||||||||||||||||||||||||||
❑ Examine the patient: Extremities
| |||||||||||||||||||||||||||||
Consider alternative diagnoses: ❑ Muscle strain or muscle tear | |||||||||||||||||||||||||||||
Is the suspected DVT a first or a recurrent episode? | |||||||||||||||||||||||||||||
First suspected episode | Suspected recurrent episode | ||||||||||||||||||||||||||||
Low pretest probability (Click here for the diagnostic approach) | Moderate pretest probability (Click here for the diagnostic approach) | High pretest probability (Click here for the diagnostic approach) | |||||||||||||||||||||||||||
Assessment of the Pre-Test Probability of DVT
Calculation of Wells Score for DVT
Variables | Score[2] |
Active cancer with either palliative therapy or treatment that is either ongoing or within the prior 6 months | 1 |
Patient was recently bedridden for at least 3 days OR Major surgery in the prior 12 weeks necessitating general or regional anesthesia |
1 |
Recent plaster immobilization, paresis or paralysis of the lower extremities | 1 |
Tenderness that is localized is the distribution of the deep veins | 1 |
Leg is entirely swollen | 1 |
Calf is swollen for 3 cm or move compared to the other calf | 1 |
Pitting edema in the symptomatic leg | 1 |
Presence of collateral superficial veins | 1 |
Previous DVT | 1 |
There is an alternative diagnosis as likely as DVT | -2 |
Interpretation of Wells Score for DVT
Score | Pretest probability[2][3] |
≥3 | High |
1 or 2 | Moderate |
0 or less | Low |
Modified Well Score
Anticoagulation
Warfarin
- Begin with 10 mg warfarin for 2 days followed by dosing based on the INR
- Start at the 1st or 2nd day of the initial parenteral therapy
- Target INR is 2-3
- Monitor INR:
- If stable, repeat INR every 12 weeks
- If stable but one value 0.5 below or above the target range, continue the same dose and repeat INR within 1-2 weeks
- Avoid NSAIDs, COX2 selective NSAIDs and some antibiotics[5]
Heparin
IV-UFH
- 80 U/kg as bolus, followed by 18 U/kg/h
- 70 U/kg as bolus, followed by 15 U/kg/h for stroke or cardiac patients
SC-UFH
- 333 U/kg as bolus, followed by 250 U/kg
LMWH: decrease dose in renal insufficiency (Creatinine clearance < 30 mL/min)
Fondaparinux
- 7.5 mg daily
- 10 mg daily if weight>100 Kg
- ↑ Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD; et al. (2012). "Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e351S–418S. doi:10.1378/chest.11-2299. PMC 3278048. PMID 22315267.
- ↑ 2.0 2.1 Wells PS, Owen C, Doucette S, Fergusson D, Tran H (2006). "Does this patient have deep vein thrombosis?". JAMA. 295 (2): 199–207. doi:10.1001/jama.295.2.199. PMID 16403932. Review in: Evid Based Med. 2006 Aug;11(4):119 Review in: ACP J Club. 2006 Jul-Aug;145(1):24
- ↑ Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L; et al. (1997). "Value of assessment of pretest probability of deep-vein thrombosis in clinical management". Lancet. 350 (9094): 1795–8. doi:10.1016/S0140-6736(97)08140-3. PMID 9428249.
- ↑ Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J; et al. (2003). "Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis". N Engl J Med. 349 (13): 1227–35. doi:10.1056/NEJMoa023153. PMID 14507948. Review in: ACP J Club. 2004 May-Jun;140(3):67
- ↑ Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ; et al. (2012). "Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e152S–84S. doi:10.1378/chest.11-2295. PMC 3278055. PMID 22315259.